132 related articles for article (PubMed ID: 1866552)
41. [Clinical study of amphotericin B in the treatment of invasive fungal infection in 111 hematological disorder patients with neutrocytopenia].
Tong HY; Zhang FJ; Xiao F; Qian WB; Meng HT; Mai WY; Tong Y; Mao LP; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):472-5. PubMed ID: 19035181
[TBL] [Abstract][Full Text] [Related]
42. Liposomal amphotericin B in critically ill paediatric patients.
Sideri G; Falagas ME; Grigoriou M; Vouloumanou EK; Papadatos JH; Lebessi E; Kafetzis DA
J Clin Pharm Ther; 2012 Jun; 37(3):291-5. PubMed ID: 21777406
[TBL] [Abstract][Full Text] [Related]
43. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data.
Ng TT; Denning DW
Arch Intern Med; 1995 May; 155(10):1093-8. PubMed ID: 7748054
[TBL] [Abstract][Full Text] [Related]
44. Role of yeasts as nosocomial pathogens & their susceptibility to fluconazole & amphotericin B.
Prasad KN; Agarwal J; Dixit AK; Tiwari DP; Dhole TN; Ayyagari A
Indian J Med Res; 1999 Jul; 110():11-7. PubMed ID: 10709333
[TBL] [Abstract][Full Text] [Related]
45. Antifungal agents used for deep-seated mycotic infections.
Terrell CL; Hermans PE
Mayo Clin Proc; 1987 Dec; 62(12):1116-28. PubMed ID: 3682956
[TBL] [Abstract][Full Text] [Related]
46. Antifungal agents used for deep-seated mycotic infections.
Hermans PE; Keys TF
Mayo Clin Proc; 1983 Apr; 58(4):223-31. PubMed ID: 6339832
[TBL] [Abstract][Full Text] [Related]
47. New methods for delivery of antifungal agents.
Meunier F
Rev Infect Dis; 1989; 11 Suppl 7():S1605-12. PubMed ID: 2690298
[TBL] [Abstract][Full Text] [Related]
48. Open label, randomised, comparative phase III safety and efficacy study with conventional amphotericin B and liposomal amphotericin B in patients with systemic fungal infection.
Bodhe PV; Kotwani RN; Kirodian BG; Kshirsagar NA; Pandya SK
J Assoc Physicians India; 2002 May; 50(5):662-70. PubMed ID: 12186120
[TBL] [Abstract][Full Text] [Related]
49. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System.
Richards MJ; Edwards JR; Culver DH; Gaynes RP
Crit Care Med; 1999 May; 27(5):887-92. PubMed ID: 10362409
[TBL] [Abstract][Full Text] [Related]
50. Torulopsis glabrata--urinary tract infections in diabetic patients in Singapore.
Tan RJ; Lim EW; Ishak B
Aust N Z J Med; 1977 Feb; 7(1):56-9. PubMed ID: 266895
[TBL] [Abstract][Full Text] [Related]
51. Continuously infused amphotericin B deoxycholate for primary treatment of invasive fungal disease in acute myeloid leukaemia.
Rothenbühler C; Held U; Manz MG; Schanz U; Gerber B
Hematol Oncol; 2018 Apr; 36(2):471-480. PubMed ID: 29431860
[TBL] [Abstract][Full Text] [Related]
52. Nosocomial infection. A continuing problem.
Dixon RE
Postgrad Med; 1977 Aug; 62(2):95-109. PubMed ID: 407557
[TBL] [Abstract][Full Text] [Related]
53. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B.
Menichetti F; Del Favero A; Martino P; Bucaneve G; Micozzi A; D'Antonio D; Ricci P; Carotenuto M; Liso V; Nosari AM; Barbui T; Fasola G; Mandelli F;
Ann Intern Med; 1994 Jun; 120(11):913-8. PubMed ID: 8172437
[TBL] [Abstract][Full Text] [Related]
54. The challenge of invasive fungal infection.
de Pauw BE; Meunier F
Chemotherapy; 1999 Jun; 45 Suppl 1():1-14. PubMed ID: 10394016
[TBL] [Abstract][Full Text] [Related]
55. Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group.
Kauffman CA; Vazquez JA; Sobel JD; Gallis HA; McKinsey DS; Karchmer AW; Sugar AM; Sharkey PK; Wise GJ; Mangi R; Mosher A; Lee JY; Dismukes WE
Clin Infect Dis; 2000 Jan; 30(1):14-8. PubMed ID: 10619726
[TBL] [Abstract][Full Text] [Related]
56. Successful treatment of Trichosporon mucoides infection with lipid complex amphotericin B and 5-fluorocytosine.
Kendirli T; Ciftçi E; Ince E; Oncel S; Dalgiç N; Güriz H; Unal E; Dogru U
Mycoses; 2006 May; 49(3):251-3. PubMed ID: 16681821
[TBL] [Abstract][Full Text] [Related]
57. Experience with liposomal amphotericin B at the Hematology-Oncology Department Children's Hospital Salata Medical School, University of Zagreb.
Konja J; Glavas B; Anicić M
Acta Biomed; 2006; 77 Suppl 2():14-6. PubMed ID: 16918061
[TBL] [Abstract][Full Text] [Related]
58. Successful treatment of fungal infections in neutropenic patients with liposomal amphotericin (AmBisome)--a report on 40 cases from a single centre.
Chopra R; Fielding A; Goldstone AH
Leuk Lymphoma; 1992; 7 Suppl():73-7. PubMed ID: 1493462
[TBL] [Abstract][Full Text] [Related]
59. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial.
Boogaerts M; Winston DJ; Bow EJ; Garber G; Reboli AC; Schwarer AP; Novitzky N; Boehme A; Chwetzoff E; De Beule K;
Ann Intern Med; 2001 Sep; 135(6):412-22. PubMed ID: 11560454
[TBL] [Abstract][Full Text] [Related]
60. Treatment of systemic fungal infections with liposomal amphotericin B.
Lopez-Berestein G; Bodey GP; Fainstein V; Keating M; Frankel LS; Zeluff B; Gentry L; Mehta K
Arch Intern Med; 1989 Nov; 149(11):2533-6. PubMed ID: 2818111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
